Scholars Central

Research articlePublished 11 Apr 2018

Efficacy, safety and economy of icotinib for advanced non-small cell lung cancer: a meta-analysis

Authors: Yan Bian, Jisheng Chen

Clinical Practice

Pages 609–618

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: To evaluate the efficacy and safety of Icotinib in the treatment of advanced Non-small Cell Lung Cancer (NSCLC). Design: Comprehensive retrieved PubMed, EMBase, Cochrane Library, CBM, CNKI, Weipu database and Wangfang database. Randomized controlled trials (RCT) about Icotinib (test group) versus Gefitinib or Erlotinib(control group) in the treatment of advanced NSCLC. The quality of included studies was evaluated and Meta-analysis was conducted. Setting: Icotinib, Erlotinib and Gefitinib belong to the first generation of EGFR-TKI. Three are now used in the treatment of advanced non-small cell lung cancer. Results: Totally 10 RCTs were enrolled, involving 1188 patients. Results of Meta-analysis showed there were no significant differences in the overall response rate (OR=1.16, 95%CI(0.90, 1.50), p=0.25), the disease control rate (OR=1.24, 95%CI(0.96, 1.60), p=0.10), the incidence of diarrhea (OR=0.76, 95%CI(0.55, 1.05), p=0.10) and the incidence of hepatic dysfunction(OR=0.45, 95%CI(0.18, 1.12), p=0.09) between 2 groups; the incidence of rash in the Icotinib group was significantly lower than the control group, there was significant difference (OR=0.68, 95%CI(0.52, 0.90), p=0.006). And the cost-effect ratio of Icotinib group has obvious advantages compared with Gefitinib and Erlotinib group. Conclusions: Based on present domestic clinical evidence, the efficacy of Icotinib for advanced NSCLC is comparable to Gefitinib or Erlotinib, but it’s incidence of rash was significantly lower than Gefitinib or Erlotinib, the tolerance of patients from Icotinib group is superior to Gefitinib or Erlotinib. Icotinib has obvious cost advantage and can be used as a routine drug choice for chemotherapy in advanced NSCLC.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Yan Bian”
  • BylineArticles whose byline prints “Jisheng Chen”